GLP-1 Check — India's GLP-1 Information & Self-Assessment Tool
All Semaglutide Brands India
Generic SemaglutideType 2 Diabetes
Dr Reddy's + USV logo

Obeda/ Usema (USV)Generic semaglutide for type 2 diabetes in India 2026

by Dr Reddy's + USV · ₹4,200/month · DCGI approved 2025 (first DCGI approval)

Active ingredient
Semaglutide (GLP-1 receptor agonist)
Indication
Type 2 Diabetes
Manufacturer
Dr Reddy's Laboratories Ltd
DCGI status
Approved 2025 (first DCGI approval)
Price (MRP)
₹4,200/month
Format
Prefilled disposable pen
4 weekly doses per pen · 2 mg and 4 mg strengths
Prescription
Schedule H — required

How Obeda compares

Obeda was the first generic semaglutide to receive DCGI approval in India — predating the broader March 2026 patent-expiry wave. Approved for type 2 diabetes only, it carries Dr Reddy's SemaKare patient-support programme: injection-technique training, tele-support, and adherence tracking. USV co-markets the same molecule as Usema under licence.

About Dr Reddy's + USV

Dr Reddy's Laboratories is one of India's largest pharma companies and a major global generics exporter. Plans to launch in 87 countries position the Obeda franchise for international expansion. USV, the licensing partner, is one of India's leading diabetes-focused pharma companies with a strong endocrinology-prescriber relationship.

Who is Obeda for?

Obeda is approved in India for type 2 diabetes mellitus in adults. Typically used as add-on therapy when metformin + lifestyle aren't achieving glycaemic targets, or as first-line in T2D patients with established cardiovascular disease, obesity, or chronic kidney disease per RSSDI 2024 guidelines.

Not sure if you qualify? Take the 5-minute Indian-guideline eligibility check →

Obeda for specific conditions

Obeda for type 2 diabetes →Obeda and prediabetes →

Obeda cost in India

MRP for Obeda: ₹4,200/month. Actual pharmacy pricing varies by city, pharmacy, and channel. Online prescription pharmacies typically offer modest discounts off MRP with cold-chain delivery; hospital pharmacy pricing is usually at MRP.

Compare with all India brands: GLP-1 therapy cost in India 2026 →

Compared to other GLP-1 brands in India

Obeda is an Indian generic semaglutide. Same active molecule as Ozempic and Wegovy (Novo Nordisk innovator brands), with clinical efficacy that follows the molecule rather than the brand. Other Indian generics include Sundae, Noveltreat, Obeda, Semaglyn, Sembolic, and Samakind — all at similar price points.

All GLP-1 comparisons →All Indian semaglutide brands →Clinical evidence library →GLP-1 blog (India) →

Obeda — frequently asked questions

Is Obeda available in India? Is it DCGI-approved?+
Yes — Obeda is DCGI-approved and currently available across India. The drug received DCGI approval in 2025 (first DCGI approval) for type 2 diabetes, manufactured by Dr Reddy's Laboratories Ltd. It is distributed through licensed retail and online prescription pharmacies and hospital pharmacies across Indian metros and most tier-2 cities. Obeda is a Schedule H drug — a doctor's prescription is required. Take the GLP-1 Check 5-minute Indian-guideline assessment to see if you qualify.
What does Obeda cost in India in 2026?+
Obeda is priced at ₹4,200/month. Actual pharmacy pricing may vary by city and channel. For brand-by-brand price comparisons across all India brands, see our cost guide. Take the GLP-1 Check 5-minute Indian-guideline assessment to see if you qualify.
Do I need a prescription to buy Obeda?+
Yes — Obeda is a Schedule H drug in India and can only be dispensed against a valid prescription from a registered medical practitioner. Any legitimate online prescription pharmacy will require you to upload your prescription before order fulfillment.
Who is Obeda for?+
Obeda is approved for type 2 diabetes in India. Indian guideline eligibility typically requires BMI ≥27.5 (obesity indication) or HbA1c above target on first-line therapy (T2D indication), often with comorbidities at BMI ≥25. Take the GLP-1 Check 5-minute Indian-guideline assessment to see if you qualify.
How does Obeda compare to Ozempic and Wegovy?+
Obeda contains the same active molecule (semaglutide) as Ozempic and Wegovy. Clinical efficacy is comparable; the difference is brand, manufacturer support, pen design, and price. Obeda (₹4,200/month) is meaningfully cheaper than Ozempic (₹5,660+/month) or Wegovy (up to ₹16,400/month) — useful for cost-sensitive patients on long-term therapy.
Where can I buy Obeda in India?+
Obeda is a Schedule H drug — available through licensed retail and online prescription pharmacies and hospital pharmacies across India with a doctor's prescription. Always buy from a licensed pharmacy to avoid counterfeit products; never use sources that dispense without verifying a prescription. Take the GLP-1 Check 5-minute Indian-guideline assessment to see if you qualify.

Source

Pearce IP — generic semaglutide India launches

GLP-1 Check is informational, not a medical diagnosis. Semaglutide is a Schedule H drug in India and requires a prescription from a registered medical practitioner. Always consult a qualified physician before starting any treatment.

Are you eligible for Obeda?

Take the free 5-minute triage to check your GLP-1 readiness against Indian clinical guidelines.

Check My Eligibility →

Looking at other brands?

See full price comparison across all 25+ DCGI-approved brands →